BOEHRINGER INGELHEIM has launched a new vaccine in the UK that offers protection to poultry from Marek’s disease.
The firm said the vaccine, named PREVEXXION® RN, was the “first innovation in the Marek’s disease category for over 40 years”.
See also: Record chicken output in 2020
It is licenced for use in day-old broilers, layers and breeders.
Boehringer Ingelheim said the strain used in the vaccine was the result of “unprecedented engineering” in vaccine design, taking traits from three existing strains to create a hybrid vaccine.
‘Protection’
Jerôme Baudon, head of poultry in Boehringer Ingelheim, said: “Our PREVEXXION® RN range provides value through innovation to poultry producers looking for continuous live production productivity improvement and effective protection in the face of Marek’s Disease challenge.
“Field and lab experiments conducted worldwide demonstrated its efficacy and early, long-lasting and robust protection through the lifespan of the birds, and against very virulent Marek’s Disease challenge.
“PREVEXXION® RN is the new gold standard for Marek’s disease vaccination programs”.
